Compounds containing astatine-211 (211At) can be used in targeted radiotherapies for prostate cancer, but deastatination in the body remains a significant hurdle.
Beckman coulter life sciences achieves industry-first with commercial release of anti-TRBC2 conjugated antibody for flow cytometry
Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, continues to lead the way with first-to-market concepts to help laboratories achieve goals